TD Cowen Downgrades Verona Pharma (VRNA) to Hold Following Merck Takeover
Tweet Send to a Friend
TD Cowen analyst Tara Bancroft downgraded Verona Pharma (NASDAQ: VRNA) from Buy to Hold with a price target of $107.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
